Background/Aims: Infliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety of infliximab in Korean patients with UC were assessed. Methods: This was a retrospective multicenter study including all adult patients who received at least one infliximab infusion for UC. Short- and long-term clinical outcomes and adverse events of infliximab therapy were evaluated, and predictors of response were identified. Results: A total of 134 UC patients were included. The indications for infliximab therapy were acute severe UC in 28%, steroid-dependency in 38%, and steroid-refractoriness in 33%, respectively. The rates of clinical response and remission were 87% and 45% at week 8. In multivariate analysis, we found significant predictors of clinical remission at week 8: immunomodulator-naïve (odds ratio [OR]=4.89, 95% confidence interval [CI]: 1.44-16.66, P=0.01), hemoglobin≥11.5g/dL (OR=4.47, 95% CI: 1.48-13.45, P=0.008), C-reactive protein≥3mg/dL (OR=4.77, 95% CI: 1.43-15.94, P=0.01), and response at week 2 (OR=20.54, 95% CI: 2.40-175.71, P=0.006). Long-term clinical response and remission rates were 71% and 52%, respectively, and mucosal healing was the only factor influencing long-term response. Adverse events related to infliximab occurred in 15% of patients, and most of them were mild and transient. Conclusions: Infliximab is effective and safe in the treatment of active UC in Korea. No history of previous immunomodulator use and high baseline C-reactive protein are independent predictors of good response.
|Number of pages||5|
|Journal||Journal of Gastroenterology and Hepatology (Australia)|
|Publication status||Published - 2013 Dec|
- Predictor of response
- Ulcerative colitis
ASJC Scopus subject areas